Formulation Development
Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing & Sourcing Powerhouse
Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, recently made its debut…..
Wheeler Bio Announces President & Chief Operating Officer
Wheeler Bio, a new CDMO specializing in the cell line development, process development, and small batch clinical production of antibodies, has announced the appointment of….
Bora Pharmaceuticals Partners With TaiRx to Manufacture Breakthrough Anti-Cancer Drug
Bora Pharmaceutical Laboratories Inc., a division of Bora Pharmaceuticals, has partnered with TaiRx, Inc., a premier Taiwan new drug development company, to manufacture a novel anti-cancer drug, CVM-1118. ….
Clearmind Applies for Patent to Treat Obesity & Metabolic Syndrome
Clearmind Medicine Inc. recently announced it has filed a provisional patent application related to metabolic syndromes including obesity. The patent application is another result of…
Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma & Fluidda
Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products, recently announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging…..
Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase 3 Trial for Relapsing Forms of Multiple Sclerosis
Mapi Pharma Ltd. recently announced positive top-line results from the GA Depot (a long acting glatiramer acetate) Phase 3 clinical trial assessing the efficacy, safety,…
Genelux Corporation Initiates Pivotal Phase 3 Trial Evaluating Olvi-Vec for the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
Genelux Corporation recently announced it has initiated OnPrime, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination…
ProtaGene Names Pharmaceutical Industry Leader Raymond Kaiser as CEO to Drive Next Stages of Growth
ProtaGene GmbH recently announced the appointment of Raymond Kaiser, PhD, as Chief Executive Officer. Ray will drive the continued innovation….
Roquette Expands Global Reach of Plant-Based Excipients Portfolio With Complete Acquisition of Crest Cellulose
Roquette recently announced its complete acquisition of India-based excipient manufacturer, Crest Cellulose. Following its purchase of a majority share in the company in 2018, this latest move….
Immunic Announces Positive Results from Single & Multiple Ascending Dose Parts of its Phase 1 Clinical Trial
Immunic, Inc. recently announced positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD)…
Decibel Therapeutics Announces Submission of IND Application for Lead Gene Therapy Candidate
Decibel Therapeutics recently announced the submission of an Investigational New Drug (IND) application to the US FDA for a Phase 1/2 clinical trial in pediatric…
Evoke Pharma Receives Notice of Allowance From USPTO for a Patent Related to GIMOTI
Evoke Pharma, Inc. recently announced the USPTO issued a Notice of Allowance for US Application No. 16/469,092 for GIMOTI. When granted, the patent will cover…
Merck Joins Accumulus Synergy as a Sponsor to Transform the Global Drug Regulatory Submission Process
Accumulus Synergy recently announced Merck, known as MSD outside the US and Canada, has joined Accumulus Synergy as a sponsor company…..
GENFIT to Acquire Clinical-Stage Biopharmaceutical Company, Expanding its Portfolio in Liver Diseases
GENFIT recently announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private…
RIGImmune Announces Acquisition of Antiviral Company Subintro
RIGImmune Inc. recently announced the acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by…
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics, Inc. recently announced the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1)…..
WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms
Synchronizing and controlling API delivery, extrusion-spheronization (E-S) offers pharmaceutical companies a robust technique to manufacture today’s most complex therapeutics.
RQM+ Acquires Jordi Labs
RQM+ recently announced the acquisition of Jordi Labs. With these new capabilities, RQM+ provides comprehensive regulatory, quality, clinical, and laboratory services, supporting market….
Lonza Expands HPAPI Multipurpose Suite for Payload-Linker Manufacturing in Visp (CH)
Lonza recently announced the completion of the expansion of its Highly Potent API (HPAPI) multipurpose suite in Visp (CH). The expansion adds development and manufacturing…
Oxford Biomedica Solutions Signs Agreement With New Partner to Deliver the Full Solution for Its AAV Programs
Oxford Biomedica Solutions LLC recently announced it has signed an agreement with an undisclosed US-based private biotechnology company. The agreement will provide The Full Solution…
